All News
This prospective study from Brazil evaluated the effect of RHZ vax in SSc pts
SSc pts had ⬆️rates of seroconversion
mean titers ⬆️ from BL
Local rxs ⬇️ in SSc pts
Systemic rxns comparable among the 2 grps
interesting data. longterm studies still needed
#ACR25 @RheumNow Abs2653 https://t.co/wJqpPrAHKG
Links:
sheila RHEUMarampa ( View Tweet)
Trends in Translational Abstracts content this year by Tomas Mustelin in the
“Abstracts that Will shape research in the near Future” Year in Preview session
@RheumNow #ACR25 https://t.co/i5CA8cxHeQ
Aurelie Najm AurelieRheumo ( View Tweet)
Thank you @drdavidliew & @DrLauraCoates ❤️ for highlighting our work. Super-responders (some were IS-Free) do exist with rituximab in #SLE Abstr#1525 @RheumNow https://t.co/S4mMAYInfT
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR25 Clinical Preview by Prof Coates to be applied tomorrow!
Early Tx
Abstr#1677 First-line TNFi for 12-mth vs step-up = better outcomes at 5-Yr
Abstr#2662 Target emulation trial = No differences in hospitalization, death/transplant RTX vs TNFi, ABA, JAK, IL-6i @RheumNow https://t.co/yostJyc5T9
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
New biomarkers in axSpA. In early axSpA (DESIR cohort), higher baseline Phospholipid transfer protein (PLTP) activity was linked to sacroiliac radiographic progression over 5 years. Lower zonulin and lipopolysaccharides (LPS) levels also associated with progression. Highlights https://t.co/1uBtR4QA97
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
@Yuz6Yusof gets a shout out from Laura Coates in the #ACR25 meeting review for his work on rituximab super-responders in SLE
@RheumNow https://t.co/EKUgmENesX
Links:
David Liew drdavidliew ( View Tweet)
Year in Preview
SLE: 52% subtherapeutic on weight based HCQ dosing
Precision prescribing needed, more so for CKD
@RheumNow #ACR25 Abstract 1722 https://t.co/8WqorQ1xJx
Jiha Lee JihaRheum ( View Tweet)
Hydroxychloroquine in SLE is all about the sweet spot. Not too hot with retinopathy, not too cold with flares, just right by the levels.
Yet drug concentrations and TDM are not commonplace in many places - time for change
Laura Coates in the #ACR25 meeting review @RheumNow https://t.co/oB3ecfSQQc
David Liew drdavidliew ( View Tweet)
Impact on handedness in PsA disease activity and structural damage: a question that often comes in my practice
Comments on Abstract #1415 presented at #ACR25
https://t.co/GilOFvXajJ
@RheumNow
Aurelie Najm AurelieRheumo ( View Tweet)
Year in Preview
GCA: GC over-prescribed, bDMARDs more effective than MTX, and more options available (TOC, JAKi)
@RheumNow #ACR25 https://t.co/L9fx1LCCnw
Links:
Jiha Lee JihaRheum ( View Tweet)
Click on the link to see my take on implantable vagal nerve stimulation RCT in RA 🎥👇🏼
https://t.co/CZrFKouSqp
@RheumNow #ACR25 #ABSTRACT1675
Aurelie Najm AurelieRheumo ( View Tweet)
“We’ve got to do better for our patients with GCA” - Laura Coates, doing the #ACR25 meeting review
She told us she is speaking about diseases outside her comfort zone but she is bang on.
As she said: not good enough real world all the people not on steroid-sparing Rx
@RheumNow https://t.co/4WiEORwPgI
David Liew drdavidliew ( View Tweet)
#ACR25 Clinical Review by Prof Coates @DrLauraCoates to be applied tomorrow!
Early Diagnosis/Tx
Abstr#2689 EHR study = IL-17i could prevent #PsA vs IL-23/TNFi
Abstr#576 Oligo → Polyarthritis progression in women, no DMARD, enthesitis, dactylitis, nail psoriasis @RheumNow https://t.co/e1hCERpCNW
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Nice to see a Dietary intervention study in the
"Top Abstracts That Will Change My Practice in the Near Future" by L. Coates for Year in Preview
Small RCT but fibres significantly improve response to treatment in the MTX treated RA group with a mean reduction of DAS28 of https://t.co/vMeIAK1P5u
Aurelie Najm AurelieRheumo ( View Tweet)
Clinical Year in Preview
SpA: no difference in efficacy rotating vs switching bDMARD MoA for next steps
@RheumNow #ACR25 #LB09 https://t.co/shCLgk7Yqz
Jiha Lee JihaRheum ( View Tweet)
Do biologics prevent PsA?
Retro cohort analysis EHR through natural language processing
5 years trends
PsO treated w/ IL-17i had lower incidence of PsA/IA than pts treated w/ IL-23i, IL-12/23i, or TNFi therapies
Adjustment on several confounding
Prospective data heavily https://t.co/W9MFaWNbWC
Aurelie Najm AurelieRheumo ( View Tweet)
ACR25 coming to a close with Clinical Year in Preview
For PsA, can biologics prevent damage? If so, which one?
Difficult to answer often b/c confounding by indication. NLP-informed propensity matching beyond demographics for clinical factors like BSA
@RheumNow #ACR25 A#2689 https://t.co/jjpb0kTo34
Jiha Lee JihaRheum ( View Tweet)
#YearInPreview at #ACR25
@DrLauraCoates introduces the session with a teaser for work that will be presented later today.
Are we entering an era in which we will be able to prevent #PsA?
Find out more at 12:00 today, Abs #2689
@RheumNow https://t.co/GDTBGNTCCd
Mrinalini Dey DrMiniDey ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Rheum Now Rheumatology Round-Up — LIVE
Join Drs. Jack Cush & Arthur Kavanaugh for this livestream with two of rheumatology’s most trusted voices: this Friday, Oct 31 at 12 PM CST for break down of the latest breakthroughs and hottest topics in rheumatology from #ACR25.
📡 Live https://t.co/GXxmtoluBc
Dr. John Cush RheumNow ( View Tweet)
